Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.25)
# 397
Out of 5,127 analysts
84
Total ratings
54.1%
Success rate
16.77%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $20.45 | +95.60% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $16.41 | +235.16% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $28.00 | +25.00% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $8.45 | +195.86% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $27.54 | +45.24% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $63.32 | +26.34% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.95 | +101.68% | 1 | Sep 3, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $18.83 | +80.56% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $41.22 | +33.43% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $33.86 | -5.49% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $135.57 | +36.46% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $73.82 | -32.27% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $24.97 | +100.24% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $98.85 | +26.45% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $60.35 | +73.99% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $801.01 | +46.69% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $64.31 | +32.17% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $23.21 | +279.15% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $186.00 | +48.39% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.52 | +674.34% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $330.11 | -29.72% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $105.92 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $120.67 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.60 | -29.05% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.20 | +270.97% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $15.41 | +1,522.32% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.18 | +747.46% | 1 | Feb 14, 2018 |
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $20.45
Upside: +95.60%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $16.41
Upside: +235.16%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $28.00
Upside: +25.00%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $8.45
Upside: +195.86%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $27.54
Upside: +45.24%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $63.32
Upside: +26.34%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.95
Upside: +101.68%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $18.83
Upside: +80.56%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $41.22
Upside: +33.43%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $33.86
Upside: -5.49%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $135.57
Upside: +36.46%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $73.82
Upside: -32.27%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $24.97
Upside: +100.24%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $98.85
Upside: +26.45%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $60.35
Upside: +73.99%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $801.01
Upside: +46.69%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $64.31
Upside: +32.17%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $23.21
Upside: +279.15%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $186.00
Upside: +48.39%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.52
Upside: +674.34%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $330.11
Upside: -29.72%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $105.92
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $120.67
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.60
Upside: -29.05%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.20
Upside: +270.97%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $15.41
Upside: +1,522.32%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.18
Upside: +747.46%